EG ·
MARVITENSE 20 5 12.5MG 30 TAB
MARVITENSE 20 5 12.5MG 30 TAB
Composition
These source-reported data require scientific review and are not treatment advice.
OLMESARTAN
· AMOUNT_PER_UNIT
Registration
Packages and prices
MARVITENSE 20 5 12.5 MG 30 TABLETS
Explainable alternatives
Candidates are informational and are not automatic authorization for substitution or dispensing.
| Product | Match | Differences | Price |
|---|---|---|---|
| MARVITENSE 40 5 12.5MG 30 TAB | EXACT_PHARMACEUTICAL_COMPOSITION | — | — EGP |
| OLMESAB 40 MG 20 TAB | EXACT_PHARMACEUTICAL_COMPOSITION | — | — EGP |
| MARVITENSE 40 525MG 30 TAB | EXACT_PHARMACEUTICAL_COMPOSITION | — | — EGP |
| OLMESAB 20 MG 20 TAB | EXACT_PHARMACEUTICAL_COMPOSITION | — | — EGP |
| MARVITENSE 40 10 25MG 30 TAB | EXACT_PHARMACEUTICAL_COMPOSITION | — | — EGP |
| Angiosartan 10mg 14tab | SAME_ACTIVE_INGREDIENT_SET | dosage_form | — EGP |
| angiosartan 20mg 21tab | SAME_ACTIVE_INGREDIENT_SET | dosage_form | — EGP |
| Angiosartan 40mg 14tab | SAME_ACTIVE_INGREDIENT_SET | dosage_form | — EGP |
| NORMESAR 20 MG 30 TAB | SAME_ACTIVE_INGREDIENT_SET | route | — EGP |
| angiosartan 40 mg 21 tab | PARTIAL_INGREDIENT_OVERLAP | substance_identity, active_moiety, strength_or_basis, route | — EGP |
| Angiosartan 40 mg 14 tab | PARTIAL_INGREDIENT_OVERLAP | substance_identity, active_moiety, strength_or_basis, route | — EGP |
| angiosartan 10 mg 28 tab | PARTIAL_INGREDIENT_OVERLAP | substance_identity, active_moiety, strength_or_basis, route | — EGP |